Lipid-lowering agents in chronic kidney disease: Do fibrates have a role?

Nature Reviews Cardiology

Volumn 10, Issue 9, 2013, Pages 547-

  Huang, Yuli ^a   Hu, Yunzhao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FENOFIBRATE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ALBUMINURIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPHYLAXIS; RENAL PROTECTION;

CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; PERCUTANEOUS CORONARY INTERVENTION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84883205647     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.15-c1     Document Type: Letter

References (12)

1. Kahn, M. R., Robbins, M. J., Kim, M. C. & Fuster, V. Management of cardiovascular disease in patients with kidney disease. Nat. Rev. Cardiol. 10, 261-273 (2013).
2. Palmer, S. C. et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 263-275 (2012).
3. Upadhyay, A. et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 251-262 (2012).
4. Barylski, M. et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol. Res. 72, 35-44 (2013).
5. Nitta, K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clin. Exp. Nephrol. 16, 522-529 (2012).
6. McCullough, P. A. & Di Loreto, M. J. Fibrates and cardiorenal outcomes. J. Am. Coll. Cardiol. 60, 2072-2073 (2012).
7. Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
8. Ting, R. D. et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care 35, 218-225 (2012).
9. Mychaleckyj, J. C. et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 35, 1008-1014 (2012).
10. Jun, M. et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 60, 2061-2071 (2012).
11. Udani, S. M. & Bakris, G. L. Do fibrates truly preserve kidney function? Nat. Rev. Endocrinol. 7, 130-131 (2011).
12. Davis, T. M. et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 54, 280-290 (2011).